Pharmalink Initiates a Pivotal Phase IIb Trial with Nefecon® in Patients with Primary IgA Nephropathy

Pharmalink Initiates a Pivotal Phase IIb Trial with Nefecon® in Patients with Primary IgA Nephropathy PR Newswire STOCKHOLM, December 18, 2012 STOCKHOLM, December 18, 2012 /PRNewswire/ -- Pharmalink AB, a Swedish specialty pharma company, today announces it has initiated a Phase IIb study with Nefecon® (Nefigan) in patients with primary IgA nephropathy at risk of developing end-stage renal